Researchers develop molecular 'calcium sponge' to tackle heart failure

February 10, 2013

Researchers at the University of Minnesota's Department of Integrative Biology and Physiology and the Lillehei Heart Institute have utilized molecular genetic engineering to optimize heart performance in models of diastolic heart failure by creating an optimized protein that can aid in high-speed relaxation similar to fast twitching muscles.

Within , calcium plays a major role in orchestrating normal function. However, in diastolic failure the calcium signaling process is slowed; rise to the peak needed for the squeezing action of the heart but don't then drop quickly enough for an efficient relaxation period – the condition known as diastolic .

University researchers were able to pinpoint a specific protein, parvalbumin – which aids in high-speed relaxation of fast twitching muscles in nature – and optimize it to become a calcium sponge for . As a result, the optimized protein, ParvE101Q, soaks up at a precise instant, allowing the heart to relax efficiently after contraction.

The advance offers a solid conceptual step forward in solving the puzzle of diastolic heart failure. The next step will be determining the best possible small molecule or gene delivery mechanism for the protein, which should allow the discovery to be used in clinics.

Their approach is outlined in the latest issue of .

"In nature, there are unique organisms known to be able to contract and relax muscles quickly," said Joseph M. Metzger, Ph.D., a University of Minnesota Medical School professor and chair of the Department of and Physiology. "We hoped research and discovery could help identify what was promoting this highly efficient activity so we could harness it for use in the heart. We've discovered that our optimized variation of parvalbumin can fulfill that role by treating diastolic heart failure."

According to Metzger, who also serves as the Maurice B. Visscher Endowed Chair in Physiology, the sponge mechanism works as a temporary depot for calcium along its normal pathway. It increases productivity in the relaxation phase of the heart cycle without negatively impacting the contracting phase.

If they can develop an ideal delivery system for the optimized protein, the researchers believe they may have found a unique clinical application to treat diastolic heart failure. Heart failure is a common killer of both men and women across the country and the rate of heart failure is increasing as our population ages and as the survival rate after recovery from first heart attack goes up.

"Heart disease and heart failure rates are growing, especially as our population ages. We hope this type of discovery may one day help pave the way to a better way to treat patients," said Metzger.

Explore further: A heart-rate-reducing medication reduces the risk of heart failure and cardiac fibrosis

Related Stories

Pacemaker could help more heart failure patients

October 5, 2012

(Medical Xpress)—A new study from Karolinska Institutet demonstrates that a change in the ECG wave called the QRS prolongation is associated with a higher rate of heart-failure mortality. According to the team that carried ...

Recommended for you

No new heart muscle cells in mice after the newborn period

November 5, 2015

A new study from Sweden's Karolinska Institutet shows that new heart muscle cells in mice are mainly formed directly after birth. After the neonatal period the number of heart muscle cells does not change, and A new study ...

Nanotechnology could spur new heart treatment

October 29, 2015

A new nanoparticle developed by University of Michigan researchers could be the key to a targeted therapy for cardiac arrhythmia, a condition that causes the heart to beat erratically and can lead to heart attack and stroke.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.